Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 3tislelizumab 1spartalizumab 1milademetan 1enzalutamide 1devimistat 1dehydroftorafur 1Tablets 1Specimen Handling 1Solutions 1Rogaratinib 1Pemetrexed 1Midazolam 1Magnetic Resonance Spectroscopy 1Letrozole 1IFL protocol 1Hydroxychloroquine 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Cetuximab 1Carboplatin 1BID protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × devimistat × Genitourinary × Clear all
NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Northwestern University

Phase 2 Recruiting
94 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡